Véronique Gelsi-Boyer

Summary

Affiliation: Institut Paoli-Calmettes
Country: France

Publications

  1. pmc Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    Haematologica 98:576-83. 2013
  2. pmc Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    J Hematol Oncol 5:12. 2012
  3. doi request reprint ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Universite de la Mediterranee Aix Marseille II, Marseille, France
    Br J Haematol 151:365-75. 2010
  4. pmc Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    BMC Cancer 8:299. 2008
  5. pmc Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
    Julien Rocquain
    Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 10:401. 2010
  6. doi request reprint Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
    Mandy Brecqueville
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    Genes Chromosomes Cancer 51:743-55. 2012
  7. doi request reprint Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations
    Raynier Devillier
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR INSERM, Institut Paoli Calmettes, Marseille, France
    Am J Hematol 87:659-62. 2012
  8. ncbi request reprint ETV6 gene rearrangements in invasive breast carcinoma
    Anne Letessier
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Institut Paoli Calmettes and UMR599 INSERM, Marseille, France
    Genes Chromosomes Cancer 44:103-8. 2005
  9. doi request reprint Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
    Br J Haematol 145:788-800. 2009
  10. pmc Myeloid malignancies: mutations, models and management
    Anne Murati
    Centre de Recherche en Cancerologie de Marseille, laboratoire d Oncologie Moléculaire UMR1068 Inserm, Institut Paoli Calmettes, 27 bd, Leï Roure, BP 30059, Marseille, 13273, France
    BMC Cancer 12:304. 2012

Collaborators

Detail Information

Publications12

  1. pmc Molecular similarity between myelodysplastic form of chronic myelomonocytic leukemia and refractory anemia with ring sideroblasts
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    Haematologica 98:576-83. 2013
    ....
  2. pmc Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    J Hematol Oncol 5:12. 2012
    ..They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment...
  3. doi request reprint ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR891 Inserm, Institut Paoli Calmettes, Universite de la Mediterranee Aix Marseille II, Marseille, France
    Br J Haematol 151:365-75. 2010
    ..The overall survival of ASXL1 mutated patients was lower than that of unmutated patients...
  4. pmc Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Marseille, France
    BMC Cancer 8:299. 2008
    ..Not much is known about the molecular biology of this disease...
  5. pmc Combined mutations of ASXL1, CBL, FLT3, IDH1, IDH2, JAK2, KRAS, NPM1, NRAS, RUNX1, TET2 and WT1 genes in myelodysplastic syndromes and acute myeloid leukemias
    Julien Rocquain
    Laboratoire d Oncologie Moleculaire, UMR891 Inserm, Institut Paoli Calmettes, Centre de Recherche en Cancerologie de Marseille, Marseille, France
    BMC Cancer 10:401. 2010
    ..Gene mutation is an important mechanism of myeloid leukemogenesis. However, the number and combination of gene mutated in myeloid malignancies is still a matter of investigation...
  6. doi request reprint Mutation analysis of ASXL1, CBL, DNMT3A, IDH1, IDH2, JAK2, MPL, NF1, SF3B1, SUZ12, and TET2 in myeloproliferative neoplasms
    Mandy Brecqueville
    Laboratoire d Oncologie Moleculaire, Centre de Recherche en Cancerologie de Marseille, UMR1068 Inserm, Institut Paoli Calmettes, Marseille, France
    Genes Chromosomes Cancer 51:743-55. 2012
    ..We found a high incidence of ASXL1 mutation in MF patients (20%) and a low incidence in PV (7%) and ET (4%) patients. Mutations in the other genes were rare (CBL, DNMT3A, IDH2, MPL, SF3B1, SUZ12, NF1) or absent (IDH1)...
  7. doi request reprint Acute myeloid leukemia with myelodysplasia-related changes are characterized by a specific molecular pattern with high frequency of ASXL1 mutations
    Raynier Devillier
    Centre de Recherche en Cancerologie de Marseille, Laboratoire d Oncologie Moleculaire, UMR INSERM, Institut Paoli Calmettes, Marseille, France
    Am J Hematol 87:659-62. 2012
    ..84%, P = 0.009). Our study showed that MRC-AML as defined in the WHO 2008 classification presents a specific mutation pattern characterized by a high frequency of ASXL1 mutations and a low rate of NPM1, FLT3, and DNMT3A mutations...
  8. ncbi request reprint ETV6 gene rearrangements in invasive breast carcinoma
    Anne Letessier
    Marseille Cancer Institute, Laboratory of Molecular Oncology, Institut Paoli Calmettes and UMR599 INSERM, Marseille, France
    Genes Chromosomes Cancer 44:103-8. 2005
    ..Of these samples, signal of sufficient quality for screening by FISH was obtained for 356. Five cases (one lobular, one nontypical secretory, one mixed, and two ductal carcinomas) showed ETV6 rearrangement...
  9. doi request reprint Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
    Véronique Gelsi-Boyer
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR891 Inserm, Institut Paoli Calmettes, France
    Br J Haematol 145:788-800. 2009
    ..These results show that ASXL1 might play the role of a tumour suppressor in myeloid malignancies...
  10. pmc Myeloid malignancies: mutations, models and management
    Anne Murati
    Centre de Recherche en Cancerologie de Marseille, laboratoire d Oncologie Moléculaire UMR1068 Inserm, Institut Paoli Calmettes, 27 bd, Leï Roure, BP 30059, Marseille, 13273, France
    BMC Cancer 12:304. 2012
    ..Given the importance of epigenetic deregulation in myeloid diseases, the use of drugs targeting epigenetic regulators appears as a most promising therapeutic approach...
  11. ncbi request reprint Combined translocation with ZNF198-FGFR1 gene fusion and deletion of potential tumor suppressors in a myeloproliferative disorder
    Anne Etienne
    Centre de Recherche en Cancerologie de Marseille, Départements d Oncologie Moléculaire et d Hématologie Moléculaire, UMR599 Inserm, Institut Paoli Calmettes, 27 Bd Lei Roure, 13009, Marseille, France
    Cancer Genet Cytogenet 173:154-8. 2007
    ..Potential tumor suppressor genes affected by the deletion by loss (IFT88, CRYL1, TACC1) or break (LATS2) may participate in the malignant process...
  12. pmc Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers
    Anne Letessier
    Centre de Recherche en Cancerologie de Marseille, Département d Oncologie Moléculaire, UMR599 Inserm Institut Paoli Calmettes, Marseille, France
    BMC Cancer 6:245. 2006
    ..Amplification status may provide diagnostic and prognostic information and may lead to new treatment strategies. Chromosomal regions 8p12, 8q24, 11q13, 17q12 and 20q13 are recurrently amplified in breast cancers...